Journal of Crohn s and Colitis · 2010 · 35 citations · 21 references
PharmacyClinical PharmacokineticsPharmacologyGastrointestinal PharmacotherapyPharmacodynamicsPopulation PharmacokineticsInflammatory Bowel DiseasePediatric Pharmacokinetics6-Thioguanine TherapyAzathioprine UseDrug Accumulation AnalysisInitiationThiopurine Therapy
BACKGROUND AND AIM: Azathioprine (AZA) has a slow onset of action in treatment of pediatric inflammatory bowel disease (IBD). It is anticipated, that this delay correlates to the kinetics of 6-thioguanine nucleotides (6-TGN) accumulation. The aim of this study was to evaluate the time to steady state of 6-TGN concentration in red blood cells. METHODS: The inclusion criteria were: a) age 0-19 years b) IBD diagnosis c) AZA treatment initiation. High performance liquid chromatography was used for the 6-TGN analysis. Concentrations of metabolites were studied in weeks 0, 1, 2, 5, and 8 after beginning of treatment. RESULTS: The inclusion criteria were matched to 18 patients with IBD. The median time to steady state of 6-TGN was 55.3 days. The mean 6-TGN concentration at the steady state achieved 326 (SD 154) pmol/8.108 erythrocytes. High erythrocyte TPMT activity corresponds to the low steady state 6-TGN concentration and vice versa. This correlation reached statistical significance (p<0.01) for the dose expressed in mg per square meter of body surface area. CONCLUSION: The time to steady state of 6-TGN erythrocyte concentration is significantly shorter than would expected according to clinical observation describe earlier.
21
The Medical Journal of Australia · 1976 · 5.3K citations
Treatment of Crohn's Disease with 6-Mercaptopurine
Daniel H. Present, Burton I. Korelitz, Nathaniel Wisch et al. · New England Journal of Medicine · 1980 · 1K citations
Development and validation of a pediatric Crohn's disease activity index.
Hyams Js, Ferry Gd, Mandel Fs et al. · PubMed · 1991 · 945 citations